John F. Milligan - May 17, 2021 Form 4 Insider Report for 4D Molecular Therapeutics Inc. (FDMT)

Role: Director
Signature: /s/ August J. Moretti, Attorney-in-Fact for John F. Milligan
Stock symbol: FDMT
Transactions as of: May 17, 2021
Transactions value $: $0
Form type: 4
Date filed: 5/19/2021, 08:33 PM
Next filing: Jun 21, 2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	FDMT	Stock Option (Right to Buy)	Award	$0	+22.5K		$0.00	22.5K	May 17, 2021	Common Stock	22.5K	$26.89	Direct	F1, F2
transaction	FDMT	Stock Option (Right to Buy)	Award	$0	+11.3K		$0.00	11.3K	May 17, 2021	Common Stock	11.3K	$26.89	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Automatically granted pursuant to the terms of the Company's non-employee director compensation program.
F2	The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).

Content

Automatically granted pursuant to the terms of the Company's non-employee director compensation program.

The stock option vests and becomes exercisable with respect to 1/3 of the total shares on May 17, 2022 and in equal monthly installments thereafter, subject to the Reporting Person continuing service to Issuer through each vesting date, until the shares are fully vested on May 17, 2024. Additionally, the stock options will vest in full upon the consummation of a Change in Control (as defined in the 2020 Incentive Award Plan).